GlassScriptPhysician profile
Grace Andrade
NPI 1285153221
$2,662.50
in general payments reported to CMS, 2019-2025
19 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $318 · 2022: $356 · 2023: $1,037 · 2024: $821 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957 · Travel and Lodging: $848 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.43 |
| Travel and Lodging | $847.60 |
| Education | $184.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,078.78 | 2021-2024 | Minimed 780g |
| Novo Nordisk INC | $293.94 | 2021-2025 | Rybelsus, Ozempic, Saxenda |
| Astellas Pharma US INC | $231.55 | 2021-2024 | Veozah |
| Lilly USA, LLC | $197.11 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $183.66 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Astrazeneca Pharmaceuticals LP | $180.60 | 2023-2024 | Airsupra, Tezspire, Breztri |
| Xeris Pharmaceuticals, INC. | $130.26 | 2021-2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $84.20 | 2021-2025 | Trelegy Ellipta |
| Pfizer INC. | $46.45 | 2023-2024 | |
| Dexcom, INC. | $46.20 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.13 | 2021-2023 | Xifaxan |
| Ibsa Pharma INC. | $32.38 | 2023-2024 | Tirosint, Licart, Licart |
| Janssen Pharmaceuticals, INC | $21.17 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.35 | 2022 | |
| Abbvie INC. | $18.66 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $17.73 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.09 | 2023 | |
| Jazz Pharmaceuticals INC. | $14.68 | 2022 | |
| Corcept Therapeutics | $14.56 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Andrade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.